Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Is The Non-Alcoholic Steatohepatitis Treatment Market Expected To Grow In Terms Of Size?

The market size for treatment of non-alcoholic steatohepatitis has seen a remarkable increase in recent times. It is predicted to rise from a value of $2.6 billion in 2024 to a whopping $3.57 billion in 2025, with a compound annual growth rate (CAGR) of 37.5%. The impressive historical growth can be ascribed to various factors such as increasing cases of NASH, enhanced awareness and diagnosis, alterations in lifestyle and the growing obesity crisis, advancements in clinical research, improved healthcare facilities and access, supportive regulations and numerous clinical trials.

Anticipated to grow exponentially in the coming years, the market size for non-alcoholic steatohepatitis treatments is predicted to reach $13.57 billion in 2029 with a compound annual growth rate (CAGR) of 39.6%. This significant expansion during the forecast period is primarily due to advances in medication invention, heightened consciousness of the disease, the growing incidence and risk factor, along with a strategic shift towards personalized healthcare. Key trends over the forecast period will focus on patient-oriented strategies, technological innovation, targeted treatments, regulatory terrain, and research advancements.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp

Which Growth Drivers Are Shaping The Non-Alcoholic Steatohepatitis Treatment Market Outlook?

The rise in the occurrence of insulin resistance has fueled the expansion of the non-alcoholic steatohepatitis treatment market. Insulin resistance, a condition where muscle, fat and liver cells fail to appropriately respond to insulin, thus hindering the easy absorption of glucose from the blood and result in high blood sugar, has been tied to unhealthy lifestyles, overconsumption of sugar, and genetic factors. The growing incidence of diabetes and other liver-related problems has amplified the cases of insulin resistance, and these are typically treated with non-alcoholic steatohepatitis treatments. As per the International Diabetes Federation’s January 2022 report, there are 537 million individuals (aged 20-79) suffering from diabetes, representing a ratio of one in ten. This figure is anticipated to increase to 643 million by 2030 and 783 million by 2045. Moreover, the American Cancer Society estimates in January 2024 that the number of new liver cancer cases will rise from 41,210 in 2023 to 41,630 in 2024. Consequently, the escalating prevalence of insulin resistance as a result of multiple liver and diabetes diseases is expected to bolster the non-alcoholic steatohepatitis treatment market.

What Are The Main Segment Classifications In The Non-Alcoholic Steatohepatitis Treatment Market?

The non-alcoholic steatohepatitis treatment market covered in this report is segmented –

1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types

2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures

3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users

Subsegments:

1) By Vitamin E And Pioglitazone: Vitamin E Supplements, Pioglitazone-Based Formulations.

2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH

3) By Elafibranor: Elafibranor-Based Treatments

4) By Selonsertib And Cenicriviroc: Selonsertib Formulations, Cenicriviroc Formulations

5) By Obeticholic Acid: Other Formulations Of Obeticholic Acid

6) By Other Drug Types: Novel Agents In Clinical Trials, Combination Therapies

How Are Industry Trends Steering The Expansion Of The Non-Alcoholic Steatohepatitis Treatment Market?

A significant trend gaining traction in the non-alcoholic steatohepatitis treatment market is the advancement of non-alcoholic steatohepatitis (NASH) drugs. Numerous businesses are investing in creating new drugs for liver disease treatment with minimized drug side effects. For instance, in May 2022, Pfizer Inc., a U.S.-based pharmaceutical and biotech company, was awarded a fast-track designation by the U.S. Food and Drug Administration (FDA) to expedite the development of non-alcoholic steatohepatitis (NASH) drugs, specifically ervogastat and clesacostat. Fast Track is a process aimed at accelerating the development of Pfizer’s experimental combo therapy for treating non-alcoholic steatohepatitis (NASH) with liver fibrosis, known as ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi).

Which Firms Are Driving Innovation Within The Non-Alcoholic Steatohepatitis Treatment Market?

Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Immuron Ltd., Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report

What Are The Emerging Regional Trends Driving The Non-Alcoholic Steatohepatitis Treatment Market?

North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2024. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=8595&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model